Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment

Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment

Pulmonary arterial hypertension (PAH) drug therapy including prostanoids, endothelin receptor antagonists, type 5 phosphodiesterase inhibitors, can improve the possibilities for treatment and control of this progressive and irreversible disease. The modern research vector aims at exploring the poten...

Full description

Bibliographic Details
Main Authors: I E Chazova, T V Martynyuk
Format: Article
Language:Russian
Published: IP Morozov P.V. 2013-12-01
Series:Системные гипертензии
Subjects:
pulmonary arterial hypertension
nitric oxide
guanylatecyclase stimulators
riociguat
phosphodiesterase type 5 inhibitors
Online Access:https://syst-hypertension.ru/2075-082X/article/view/28994

Internet

https://syst-hypertension.ru/2075-082X/article/view/28994

Similar Items